, Tracking Stock Market Picks
Enter Symbol:
Array Biopharma Inc. (ARRY) [hlAlert]

up 88.38 %

Array Biopharma Inc. (ARRY) upgraded to Buy with price target $4.25 by UBS

Posted on: Friday,  Jul 23, 2010  11:25 AM ET by UBS

UBS rated Buy Array Biopharma Inc. (NASDAQ: ARRY) on 07/23/2010, when the stock price was $3.10. Since
then, Array Biopharma Inc. has gained 88.39% as of 01/15/2016's recent price of $5.84.
If you would have followed this UBS's recommendation on ARRY, you would have gained 88.38% of your investment in 2002 days.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/23/2010 11:25 AM Buy
3.10 4.25
as of 12/31/2010
1 Week down  -4.82 %
1 Month down  -7.78 %
3 Months down  -8.35 %
1 YTD up  26.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/22/2010 8:25 AM Hold
11/5/2009 8:25 AM Buy
9/8/2009 8:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy